Breast reduction surgery and breast cancer risk: Does reduction mammaplasty have a role in primary prevention strategies for women at high risk of breast cancer?

被引:20
作者
Tarone, RE
Lipworth, L
Young, VL
McLaughlin, JK
机构
[1] Int Epidemiol Inst, Rockville, MD 20850 USA
[2] Vanderbilt Univ, Med Ctr, Dept Med & Prevent Med, Nashville, TN USA
[3] Bodyaesthet Plast Surg Ctr, St Louis, MO USA
关键词
D O I
10.1097/01.PRS.0000122407.07002.95
中图分类号
R61 [外科手术学];
学科分类号
摘要
to reduce breast cancer incidence in women with a high inherited susceptibility to breast cancer. For the majority of high-risk women, however, bilateral prophylactic mastectomy is not an acceptable option for primary prevention of breast cancer. Several epidemiological follow-up Studies have indicated that there may be a substantial reduction in breast. cancer risk among women who have undergone breast reduction surgery. The authors, reviewed the evidence from these studies, with emphasis on the problems inherent in interpreting the results of nonexperimental studies of elective medical procedures. Although Such observational studies cannot demonstrate definitively that reduction mammaplasty reduces the risk of breast cancer, the evidence from these studies is sufficiently strong to warrant the evaluation of breast reduction surgery as an option for primary prevention in clinical Studies of women at increased risk of breast cancer. The availability, of a more acceptable surgical option for primary prevention of breast cancer could increase the number of women willing to choose risk reduction surgery and thus may result in an overall reduction in breast cancer mortality among high-risk women.
引用
收藏
页码:2104 / 2110
页数:7
相关论文
共 59 条
[31]   Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation [J].
Klaren, HM ;
van't Veer, LJ ;
van Leeuwen, FE ;
Rookus, MA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (13) :941-947
[32]   Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing [J].
Lerman, C ;
Hughes, C ;
Croyle, RT ;
Main, D ;
Durham, C ;
Sndyer, C ;
Bonney, A ;
Lynch, JF ;
Narod, SA ;
Lynch, HT .
PREVENTIVE MEDICINE, 2000, 31 (01) :75-80
[33]   BREAST-CANCER INCIDENCE SUBSEQUENT TO SURGICAL REDUCTION OF THE FEMALE BREAST [J].
LUND, K ;
EWERTZ, M ;
SCHOU, G .
SCANDINAVIAN JOURNAL OF PLASTIC AND RECONSTRUCTIVE SURGERY AND HAND SURGERY, 1987, 21 (02) :209-212
[34]  
Lynch HT, 1997, CANCER-AM CANCER SOC, V79, P2219, DOI 10.1002/(SICI)1097-0142(19970601)79:11<2219::AID-CNCR21>3.0.CO
[35]  
2-Y
[36]   Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer [J].
McDonnell, SK ;
Schaid, DJ ;
Myers, JL ;
Grant, CS ;
Donohue, JH ;
Woods, JE ;
Frost, MH ;
Johnson, JL ;
Sitta, DL ;
Slezak, JM ;
Crotty, TB ;
Jenkins, RB ;
Sellers, TA ;
Hartmann, LC .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (19) :3938-3943
[37]   Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation [J].
Meijers-Heijboer, EJ ;
Verhoog, LC ;
Brekelmans, CTM ;
Seynaeve, C ;
Tilanus-Linthorst, MMA ;
Wagner, A ;
Dukel, L ;
Devilee, P ;
van den Ouweland, AMW ;
van Geel, AN ;
Klijn, JGM .
LANCET, 2000, 355 (9220) :2015-2020
[38]   Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. [J].
Meijers-Heijboer, H ;
van Geel, B ;
van Putten, WLJ ;
Henzen-Logmans, SC ;
Seynaeve, C ;
Menke-Pluymers, MBE ;
Bartels, CCM ;
Verhoog, LC ;
van den Ouweland, AMW ;
Niermeijer, MF ;
Brekelmans, CTM ;
Klijn, JGM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03) :159-164
[39]   Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation [J].
Meijers-Heijboer, H ;
Brekelmans, CTM ;
Menke-Pluymers, M ;
Seynaeve, C ;
Baalbergen, A ;
Burger, C ;
Crepin, E ;
van den Ouweland, AWM ;
van Geel, B ;
Klijn, JGM .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (09) :1675-1681
[40]  
Narod S, 2001, NEW ENGL J MED, V345, P1498